Monday, September 7, 2026
← Back to archivePolicy
Policy•STAT News•Sep 5, 2026
Opinion: What STAT readers think about M.D. vs. D.O., AI in medicine, surrogacy, and more
background ▾
Policy•Fierce Biotech•Sep 4, 2026
A year on from Big Pharma’s pull-back from the UK, has anything changed?
background ▾
- •The UK-US pharmaceutical trade deal and reduced NHS rebate rate (14.5% vs. 22.9% in 2025) have already convinced AstraZeneca to restart major R&D investment, signaling that pricing concessions can reverse industry divestment
- •Merck & Co., Eli Lilly, and Sanofi have not confirmed any reversal of their 2025 pullback decisions despite the improved pricing environment, suggesting either delayed decision-making or deeper strategic concerns about the UK market
- •Watch for: Announcements from Merck, Lilly, and Sanofi in coming quarters on whether the improved rebate framework and US trade agreement are sufficient to restart abandoned R&D projects (Merck's £1.3B London center, Lilly's Gateway Labs, Sanofi's blanket investment freeze)
AstraZenecaMerck & Co.Eli Lilly
→ Read original articlePolicy•Endpoints News•Sep 4, 2026
The race to make new Ebola vaccines faces a cash crunch
background ▾
- •Ebola vaccine development is being constrained by inadequate funding despite rising outbreak urgency in Africa
- •Organizations leading vaccine development efforts are experiencing cash shortages that threaten program timelines
- •Success of new vaccine candidates depends on securing public health funding and political commitment
Ebola vaccines
→ Read original articlePolicy•STAT News•Sep 4, 2026
Disabled workers at greater risk of losing health insurance
background ▾
- •Disabled workers have substantially lower employer health insurance rates than the general population, creating a coverage gap as Medicaid work requirements phase in during 2024-2025
- •This policy intersection creates dual risk: disabled workers both lack employer coverage and face Medicaid disenrollment, potentially leaving millions uninsured
- •Monitor state implementation of Medicaid work requirements and any federal legislative response to carve-outs for disabled populations
Policy•KFF•Aug 27, 2026
Different State Regulatory Approaches Reflect Open Questions About AI Mental Health Tools — The Monitor
background ▾
- •States are adopting fundamentally different regulatory models—some restricting AI from claiming to provide therapy, while others focus on data protection and disclosure requirements—creating a patchwork that lacks coherent federal oversight.
- •Documented risks include AI reinforcing false health beliefs and contributing factors in suicide cases, with 28% of adults under 30 using AI for mental health advice, establishing regulatory urgency.
- •The core unresolved question is regulatory classification: treating AI as a clinical tool, consumer product, or regulated healthcare will determine liability, oversight requirements, and market access across states.
Market Access
Market Access•Fierce Biotech•Sep 4, 2026
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
background ▾
- •Bofanglutide's bi-weekly dosing differentiates it from once-weekly GLP-1 competitors and could provide commercial advantage if efficacy/safety data in global Phase 3 matches earlier trials.
- •The partnership demonstrates significant investor confidence in Gan & Lee's pipeline and valuates the molecule at nearly $1 billion—substantial even for the crowded GLP-1 space, suggesting strong internal trial data.
- •Watch for global Phase 3 trial initiation and readout timelines; European regulatory pathway and head-to-head efficacy data versus semaglutide and tirzepatide will be critical to market positioning and payer adoption.
Menarini GroupGan & Lee PharmaceuticalsNovo NordiskbofanglutideOzempic (semaglutide)tirzepatide
→ Read original articleMarket Access•Endpoints News•Sep 7, 2026
Claret says its latest fund will have larger focus on European life sciences
background ▾
- •Claret Capital Partners Fund IV raises €575 million with expanded European life sciences focus
Claret Capital Partners
→ Read original articleMarket Access•Fierce Biotech•Sep 6, 2026
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
background ▾
- •ADARx plans to deploy IPO capital across six siRNA programs spanning complement disorders, thrombosis prevention, neurodegeneration, and obesity—a broad clinical agenda that increases execution risk but diversifies pipeline value
- •AbbVie's $335 million upfront deal in 2025 validates the next-generation siRNA platform and de-risks the IPO, though the extent of AbbVie's option-exercise commitment and royalty structure remains undisclosed
- •Monitor phase 2 readouts for agazisiran in IgA nephropathy and PNH, phase 3 enrollment in onvuzosiran for hereditary angioedema, and the company's ability to advance ADX-626 and obesity/Alzheimer's programs on stated timelines post-IPO
ADARx PharmaceuticalsAbbVieBlackrockagazisiranonvuzosiranADX-626
→ Read original articleMarket Access•Endpoints News•Sep 5, 2026
AbbVie-allied ADARx aims for IPO with 3 drugs in the clinic
background ▾
- •ADARx is pursuing public markets with three clinical-stage RNA interference programs, signaling confidence in near-term catalysts and investor appetite for RNAi therapeutics
- •AbbVie's involvement as a supporter provides credibility and potential downstream partnership opportunity
ADARx PharmaceuticalsAbbVie
→ Read original articleMarket Access•Fierce Biotech•Sep 4, 2026
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
background ▾
- •Zanvastro is the first FDA-approved therapy addressing the underlying genetic cause of Alexander disease, establishing a landmark precedent in ultra-rare neurodegenerative diseases
- •This approval validates Ionis's independent neurology ASO pipeline and demonstrates differentiation from Biogen-partnered programs (Spinraza, Qalsody), suggesting stronger internal development capabilities
- •Monitor Ionis's clinical pipeline for additional rare neurology indications using similar GFAP or other single-gene targets, as this success likely accelerates investment in ultra-orphan CNS programs industry-wide
Ionis PharmaceuticalsBiogenUniversity of WisconsinzilganersenZanvastroSpinraza
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 4, 2026
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
background ▾
- •Invivyd will report phase 3 data for VYD2311 in Q3 2024, evaluating prevention of symptomatic COVID in adults and adolescents—a focused endpoint in a competitive landscape dominated by vaccines.
- •Marc Elia's dual appointment as chairman and CEO signals preparation for commercialization decision-making, though dual roles may create governance questions if trial data is positive or negative.
InvivydVertex PharmaceuticalsInventivaVYD2311lanifibranor
→ Read original articleClinical Trials•Endpoints News•Sep 5, 2026
CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
background ▾
- •Novartis halted an experimental CAR-T program after three patient deaths, representing a material safety signal requiring immediate clinical hold
- •The deaths occurred in an investigational CAR-T therapy distinct from approved Kymriah, suggesting safety issues may not be limited to a single program approach
- •Watch for regulatory communications (FDA/EMA guidance), disclosure of autopsy/safety findings, and whether the halt extends to related Novartis CAR-T candidates
NovartisEli LillyKymriah
→ Read original articleClinical Trials•Endpoints News•Sep 7, 2026
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility
background ▾
- •Novo Nordisk has discontinued two Phase 3 trials of ziltivekimab for cardiovascular indications due to futility, indicating the drug is unlikely to meet primary endpoints
- •This is the third or subsequent trial termination for ziltivekimab, suggesting a fundamental efficacy challenge with the molecule or target in heart disease
- •Watch for: whether Novo Nordisk continues development of ziltivekimab in other indications, or whether the company pivots its IL-6 inhibition strategy entirely
Novo Nordiskziltivekimab
→ Read original articleClinical Trials•Fierce Biotech•Sep 5, 2026
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
background ▾
- •Pelacarsen failed its primary endpoint in a well-powered 8,323-patient phase 3 trial, marking the first major late-stage setback for the nascent Lp(a)-lowering drug category and creating doubt about whether 72% Lp(a) reduction is sufficient to alter cardiovascular outcomes.
- •Deeper Lp(a) inhibition (>90%) achieved by Amgen and Eli Lilly's RNA interference candidates may be required to see clinical benefit, or alternatively, the causal relationship between Lp(a) lowering and CVD risk reduction may be weaker than hypothesized.
- •Full trial data release at an upcoming medical meeting will be critical to determine whether pelacarsen showed a directional (but statistically non-significant) benefit in subgroups or a truly neutral result—a distinction that will shape whether competitors and the field continue investment in deeper-inhibition approaches.
NovartisIonisAmgenpelacarsenolpasiranlepodisiran
→ Read original article